In addition, CD26 expression has also been associated with higher degree of disease aggressiveness and worse survival outcomes in T-LBL/T-ALL compared to patients with CD26 negative tumors (p < 0.0001). The gene discussed is DPP4; the disease is acute lymphoblastic leukemia.